All In Biotech

Drug Trial Radar · NCT06507891

A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

A Phase Ib, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance , Pharmacokinetics and Effectiveness of TQ-A3334 Tablets in Patients With Advanced Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

30

Actual

Start

Jul 6, 2020

Primary completion

Aug 25, 2023

Study completion Jun 4, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules in patients with non-small cell lung cancer.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • TQ-A3334 tabletsDrug

    TQ-A3334 is a highly efficient and highly selective Toll-like receptor-7 (TLR-7) agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including interferon alpha (IFN-α), Interleukin 12 (IL-12), Tumor Necrosis Factor Alpha (TNF-α), and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.

  • TQ-A3334 tablets + Anlotinib capsulesDrug

    TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect. Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AE)Time frame: Baseline up to 21 days
  2. Dose limited toxicity (DLT)Time frame: Baseline up to 21 days
  3. Maximum tolerable dose (MTD)Time frame: Baseline up to 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jingling Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.